

What is claimed:

- (1) A method treating and/or preventing allergic and inflammatory conditions of the skin or airway passages in a human of 12 years and older in need of such treating and /or preventing which comprises administering an effective amount of desloratadine for a time sufficient to produce a geometric mean steady state maximum plasma concentration of desloratadine in the range of about 2.90 ng/mL to about 4.54 ng/mL, or an arithmetic mean steady state maximum plasma concentration of desloratadine in the range of about 3.2 ng/mL to about 5.0 ng/mL.
- (2) The method of claim 1 wherein the geometric mean T_{\max} is in the range of about 1.60 to about 2.50 hours.
- (3) The method of claim 1 wherein the arithmetic mean T_{\max} is in the range of about 2.54 to about 3.96 hours.
- (4) A method treating and/or preventing allergic and inflammatory conditions of the skin or airway passages in a human of 12 years and older in need of such treating and /or preventing which comprises administering an effective amount of desloratadine for a time sufficient to produce a geometric mean steady state maximum plasma concentration of 3-OH-desloratadine in the range of about 1.50 ng/mL to about 2.34 ng/mL, or an arithmetic mean steady state maximum plasma concentration of 3-OH-desloratadine in the range of about 1.60 ng/mL to about 2.50 ng/mL.
- (5) The method of claim 4 wherein the geometric mean T_{\max} is in the range of about 4.00 to about 6.25 hours.

(6) The method of claim 4 wherein the arithmetic mean T_{\max} is in the range of about 3.80 to about 5.95 hours.

(7) The method of claim 4 wherein the amount of desloratadine is about 5.0 mg/day, in single or divided doses

5 (8) The method of claim 1 wherein the amount of desloratadine is about 5.0 mg/day, in single or divided doses.

(9) The method of claim 1 wherein the amount of desloratadine is about 5 mg/day.

10 (10) The method of claim 1 wherein the amount of desloratadine is about 2.5 mg/ twice a day

(11) The method of claim 1 wherein the geometric mean AUC(0-24hr) for desloratadine is in the range of about 39.5 ng.hr/mL to about 61.8 ng.hr/mL.

(12) The method of claim 1 wherein the arithmetic mean AUC(0-24hr) for desloratadine is in the range of about 45.5 ng.hr/mL to about 71.1 ng.hr/mL.

15 (13) The method of claim 4 wherein the geometric mean AUC(0-24hr) for 3-OH-desloratadine is in the range of about 24.3 ng.hr/mL to about 38.0 ng.hr/mL.

(14) The method of claim 4 wherein the arithmetic mean AUC(0-24hr) for 3-OH-desloratadine is in the range of about 25.8 ng.hr/mL to about 40.4 ng.hr/mL.

20 (15) The method of claim 1 wherein the allergic reaction is seasonal allergic rhinitis, perennial allergic rhinitis, atopic dermatitis, urticaria or allergic asthma.

(16) A method of treating and/or preventing seasonal or perennial allergic rhinitis in a human of 12 years and older which comprises administering an effective amount of desloratadine for a time sufficient to produce a geometric mean steady state maximum plasma concentration of desloratadine in the range

of about 2.90 ng/mL to about 4.54 ng/mL, or a arithmetic mean steady state maximum plasma concentration of desloratadine in the range of about 3.2 ng/mL to about 5.0 ng/mL.

(17) The method of claim 16 wherein the geometric mean T_{max} is in the range of about 1.60 to about 2.50 hours.

(18) The method of claim 16 wherein the arithmetic mean T_{max} is in the range of about 2.54 to about 3.96 hours.

(19) A method of treating and/or preventing seasonal or perennial allergic rhinitis in a human of 12 years and older which comprises administering an effective amount of 3-OH-desloratadine for a time sufficient to produce a geometric mean steady state maximum plasma concentration of desloratadine in the range of about 1.50 ng/mL to about 2.34 ng/mL, or a arithmetic mean steady state maximum plasma concentration of 3-OH-desloratadine in the range of about 1.60 ng/mL to about 2.50 ng/mL.

(20) The method of claim 19 wherein the geometric mean T_{max} is in the range of about 4.00 to about 6.25 hours.

(21) The method of claim 19 wherein a arithmetic mean steady state maximum plasma concentration of 3 OH-desloratadine in the range of about 1.60 ng/mL to about 2.50 ng/mL is produced

(22) The method of claim 19 wherein the arithmetic mean T_{max} is in the range of about 3.80 to about 5.95 hours.

(23) The method of claim 19 wherein the amount of desloratadine is about 5.0 mg/day, in single or divided doses.

(24) The method of claim 16 wherein the amount of desloratadine is about 5.0 mg/day, in single or divided doses.

(25) The method of claim 16 wherein the amount of desloratadine is about 5 mg/day.

5 (26) The method of claim 16 wherein the amount of desloratadine is about 2.5 mg/ twice a day

(27) The method of claim 16 wherein the geometric mean AUC(0-24hr) for desloratadine is in the range of about 39.5 ng.hr/mL to about 61.8 ng.hr/mL.

10 (28) The method of claim 16 wherein the arithmetic mean AUC(0-24hr) for desloratadine is in the range of about 45.5 ng.hr/mL to about 71.1 ng.hr/mL.

(29) The method of claim 19 wherein the geometric mean AUC(0-24hr) for 3-OH-desloratadine is in the range of about 24.3 ng.hr/mL to about 38.0 ng.hr/mL.

(30) The method of claim 19 wherein the arithmetic mean AUC(0-24hr) for 3-OH-desloratadine is in the range of about 25.8 ng.hr/mL to about 40.4 ng.hr/mL.

15 (31) A method of treating and/or preventing atopic dermatitis or urticaria in a human of 12 years and older in need of such which comprises administering an effective amount of desloratadine for a time sufficient to produce a geometric mean steady state maximum plasma concentration of desloratadine in the range of about 2.90 ng/mL to about 4.54 ng/mL, or a arithmetic mean steady state
20 maximum plasma concentration of desloratadine in the range of about 3.2 ng/mL to about 5.0 ng/mL.

(32) The method of claim 31 wherein the geometric mean T_{max} is in the range of about 1.60 to about 2.50 hours.

(33) The method of claim 31 wherein the arithmetic mean T_{\max} is in the range of about 2.54 to about 3.96 hours.

(34) A method of treating and/or preventing atopic dermatitis or urticaria in a human of 12 years and older in need of such which comprises administering an effective amount of desloratadine for a time sufficient to produce a geometric mean steady state maximum plasma concentration of 3 OH-desloratadine in the range of about 1.50 ng/mL to about 2.34 ng/mL, or a arithmetic mean steady state maximum plasma concentration of desloratadine in the range of about 1.6 ng/mL to about 2.50 ng/mL.

(35) The method of claim 34 wherein the geometric mean T_{\max} of 3 OH-desloratadine is in the range of about 4.00 to about 6.25 hours.

(36) The method of claim 34 wherein the arithmetic mean T_{\max} of 3 OH-desloratadine is in the range of about 3.80 to about 5.95 hours.

(37) The method of claim 34 wherein the amount of desloratadine is about 5.0 mg/day, in single or divided doses.

(38) The method of claim 31 wherein the amount of desloratadine is about 5.0 mg/day, in single or divided doses.

(39) The method of claim 31 wherein the amount of desloratadine is about 5 mg/day.

(40) The method of claim 31 wherein the amount of desloratadine is about 2.5 mg/ twice a day.

(41) The method of claim 31 wherein the geometric mean AUC(0-24hr) for desloratadine is in the range of about 39.5 ng.hr/mL to about 61.8 ng.hr/mL.

(42) The method of claim 31 wherein the arithmetic mean AUC(0-24hr) for desloratadine is in the range of about 45.5 ng.hr/mL to about 71.1 ng.hr/mL.

(43) The method of claim 34 wherein the geometric mean AUC(0-24hr) for 3-OH-desloratadine is in the range of about 24.3 ng.hr/mL to about 38.0 ng.hr/mL.

5 (44) The method of claim 34 wherein the arithmetic mean AUC(0-24hr) for 3-OH-desloratadine is in the range of about 25.8 ng.hr/mL to about 40.4 ng.hr/mL.

(45) A method of treating and/or preventing the nasal and non-nasal symptoms of seasonal and perennial allergic rhinitis and for treating chronic idiopathic urticaria in a human of 12 years and older in need of such treating and /or
10 preventing which comprises administering to said human about 5.0 mg of desloratadine once a day for about 10 days to produce at an arithmetic mean time to maximum plasma concentration (T_{max}) of about 3 hours post dose, an arithmetic mean steady state maximum plasma concentration(C_{max}) of desloratadine of about 4 ng/mL, and an area under the concentration-time curve
15 of 56.9ng.hr/mL of desloratadine.

(46) The method of claim 45 wherein the arithmetic mean steady state maximum plasma concentration(C_{max}) of 3-OH-desloratadine produced post dose at an arithmetic mean time to maximum plasma concentration (T_{max}) of about 4.8 hours, is about 2 ng/mL, and an area under the concentration-time curve of
20 desloratadine is about 32.3 ng.hr/mL.

(47) The method of claim 46 wherein the arithmetic mean AUC(0-24hr) for 3-OH-desloratadine is in the range of about 25.8 ng.hr/mL to about 40.4 ng.hr/mL.

(48) A method of treating and/or preventing the nasal and non-nasal symptoms of seasonal and perennial allergic rhinitis and/or of treating chronic idiopathic

urticaria in a human of 12 years and older in need of such treating and /or preventing which comprises administering an effective amount of desloratadine for a time sufficient to produce a steady state geometric mean plasma concentration of desloratadine in the range of about 2.90 ng/mL to about 4.54 ng/mL, or a

5 steady state arithmetic mean maximum plasma concentration of desloratadine in the range of about 3.2 ng/mL to about 5.0 ng/mL.

(49) The method of claim 48 wherein the arithmetic mean steady state maximum plasma concentration (C_{max}) of 3-OH-desloratadine produced post dose at arithmetic mean time to maximum plasma concentration (T_{max}) in the range of

10 about 3.80 hours to 5.95 hours, is in the range about 1.60 ng/mL to about 2.50 ng/mL, and an area under the concentration-time curve of desloratadine was in the range of about 25.8 ng.hr/mL to about 40.4 ng.hr/mL.

(50) The method of claim 48 wherein the amount of desloratadine is about 2.5 mg/twice a day.

15 (51) The method of claim 48 wherein the amount of desloratadine is about 5 mg/day.

(52) A method of treating and/or preventing the nasal and non-nasal symptoms of seasonal and perennial allergic rhinitis and/or of treating chronic idiopathic urticaria in a human of 12 years and older in need of such treating and /or

20 preventing which comprises administering to said human about 5.0 mg of desloratadine once a day for about 10 days to produce an arithmetic mean steady state maximum plasma concentration (C_{max}) of desloratadine at an arithmetic mean time to maximum plasma concentration (T_{max}) of about 3 hours post dose.

(53) The method of claim 52 wherein the arithmetic mean steady state maximum plasma concentration (C_{max}) of 3-OH-desloratadine produced at arithmetic mean time to maximum plasma concentration (T_{max}) of about 4.8 hours post dose, is about 2.0 ng/mL, and an area under the concentration-time curve of desloratadine is about 32.3 ng.hr/mL.

(54) A method of treating and/or preventing the nasal and non-nasal symptoms of seasonal and perennial allergic rhinitis and/or of treating chronic idiopathic urticaria in a human of 12 years and older in need of such treating and /or preventing which comprises administering to said human about 5.0 mg of desloratadine once a day for about 10 days to produce at an arithmetic mean time to maximum plasma concentration (T_{max}) of about 3 hours post dose, an arithmetic mean steady state maximum plasma concentration (C_{max}) of desloratadine of about 4 ng/mL, and an area under the concentration-time curve of 56.9 ng.hr/mL of desloratadine.

(55) The method of claim 54 wherein the arithmetic mean steady state maximum plasma concentration (C_{max}) of 3-OH-desloratadine produced at arithmetic mean time to maximum plasma concentration (T_{max}) of about 4.8 hours post dose, is about 2.0 ng/mL, and an area under the concentration-time curve of desloratadine is about 32.3 ng.hr/mL.

(56) A method of treating chronic idiopathic urticaria in a human of 12 years and older in need of such treating and /or preventing which comprises administering to said human about 5.0 mg of desloratadine once a day for about 10 days to produce at an arithmetic mean time to maximum plasma concentration (T_{max}) of about 3 hours post dose, an arithmetic mean steady state maximum plasma

concentration (C_{\max}) of desloratadine of about 4 ng/mL, and an area under the concentration-time curve of 56.9 ng.hr/mL of desloratadine.

(57) The method of claim 56 wherein the arithmetic mean steady state maximum plasma concentration(C_{\max}) of 3-OH-desloratadine produced at

5 arithmetic mean time to maximum plasma concentration (T_{\max}) of about 4.80 hours post dose, is about 2.0 ng/mL, and an area under the concentration-time curve of desloratadine is about 32.3 ng.hr/mL.

(58) A method of treating and/or preventing the nasal and non-nasal symptoms

10 of seasonal and perennial allergic rhinitis in a human of 12 years and older in need of such treating and /or preventing which comprises administering to said human about 5.0 mg of desloratadine once a day for about 10 days to produce at an arithmetic mean time to maximum plasma concentration (T_{\max}) of about 3 hours post dose, an arithmetic mean steady state maximum plasma concentration
15 (C_{\max}) of desloratadine of about 4 ng/mL, and an area under the concentration-time curve of 56.9 ng.hr/mL of desloratadine.

(59) The method of claim 58 wherein the arithmetic mean steady state maximum plasma concentration(C_{\max}) of 3-OH-desloratadine produced at

20 arithmetic mean time to maximum plasma concentration (T_{\max}) of about 4.80 hours post dose, is about 2.0 ng/mL, and an area under the concentration-time curve of desloratadine is about 32.3 ng.hr/mL.